125982-19-6

Basic information

• Product Name: (4S)-4-[[(1,1-Dimethylethoxy)carbonyl]amino]-5-hydroxypentanoic acid ethyl ester
• Synonyms: (4S)-4-[[(1,1-Dimethylethoxy)carbonyl]amino]-5-hydroxypentanoic acid ethyl ester
• CAS NO: 125982-19-6
• Molecular Formula: C₁₂H₂₃NO₅
• Molecular Weight: 261.31472
• Mol File: 125982-19-6.mol

Chemical Properties

• Boiling Point: 388.3±37.0 °C(Predicted)
• Appearance: /
• Density: 1.087±0.06 g/cm3(Predicted)
• PKA: 11.88±0.46(Predicted)
• CAS DataBase Reference: (4S)-4-[[(1,1-Dimethylethoxy)carbonyl]amino]-5-hydroxypentanoic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (4S)-4-[[(1,1-Dimethylethoxy)carbonyl]amino]-5-hydroxypentanoic acid ethyl ester(125982-19-6)
• EPA Substance Registry System: (4S)-4-[[(1,1-Dimethylethoxy)carbonyl]amino]-5-hydroxypentanoic acid ethyl ester(125982-19-6)

Safety Data

• Hazardous Substances Data: 125982-19-6(Hazardous Substances Data)

Usage

Uses

Used in Organic Chemistry:
(4S)-4-[[(1,1-Dimethylethoxy)carbonyl]amino]-5-hydroxypentanoic acid ethyl ester is used as a building block for the synthesis of other organic molecules due to its unique structural features, including the ethyl ester, carbonyl, and amino groups. These functional groups allow for various chemical reactions and modifications, expanding the compound's applicability in organic chemistry.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (4S)-4-[[(1,1-Dimethylethoxy)carbonyl]amino]-5-hydroxypentanoic acid ethyl ester is used for exploring its potential pharmacological properties. The presence of the ethyl ester, carbonyl, and amino groups may contribute to the compound's interaction with biological targets, making it a promising candidate for drug development and therapeutic applications.
Used in Drug Synthesis:
(4S)-4-[[(1,1-Dimethylethoxy)carbonyl]amino]-5-hydroxypentanoic acid ethyl ester is employed as a key intermediate in the synthesis of pharmaceutical drugs. Its structural features enable the creation of novel drug candidates with potential therapeutic benefits, particularly in the treatment of various diseases and medical conditions.
Used in Drug Delivery Systems:
(4S)-4-[[(1,1-Dimethylethoxy)carbonyl]amino]-5-hydroxypentanoic acid ethyl ester may also be utilized in the development of drug delivery systems, where its structural properties can be leveraged to improve the bioavailability, targeting, and overall efficacy of pharmaceutical agents. This application can lead to the creation of more effective and targeted drug therapies, enhancing patient outcomes and treatment options.

Upstream product

• 65487-73-2 (S)-2-((tert-butoxycarbonyl)amino)-5-ethoxy-5-oxopentanoic acid 
• 126073-39-0 2-tert-butoxycarbonylamino-pentanedioic acid 5-(2,5-dioxo-pyrrolidin-1-yl) ester 5-ethyl ester 
• 1119-33-1 (S)-2-Amino-pentanedioic acid 5-ethyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 691-64-5 di-tert-butyl oxalate 

Downstream Products

• 125982-23-2 ⁽⁵⁾-tert-butyl (6-oxotetrahydro-2H-pyran-3-yl)carbamate 
• 487-79-6 (-)-kainic acid 
• 132430-61-6 (2RS,4S)-4-<(tert-butoxycarbonyl)amino>-2-phenylseleno-5-pentanolide 
• 133328-97-9 [(3S,4R)-4-(Benzo[1,3]dioxol-5-yl-phenylsulfanyl-methyl)-6-oxo-tetrahydro-pyran-3-yl]-carbamic acid tert-butyl ester 
• 133328-98-0 {(3S,4R)-4-[(3-Methoxy-phenyl)-phenylsulfanyl-methyl]-6-oxo-tetrahydro-pyran-3-yl}-carbamic acid tert-butyl ester 
• 133328-98-0 {(3S,4S)-4-[(3-Methoxy-phenyl)-phenylsulfanyl-methyl]-6-oxo-tetrahydro-pyran-3-yl}-carbamic acid tert-butyl ester 
• 222027-26-1 2,2-dimethyl-4-(4-oxo-3-phenoxy-cyclohex-2-enylmethyl)-oxazolidine-3-carboxylic acid tert-butyl ester 

Relevant articles and documents

A synthetic approach to diaryl ethers using the Robinson annulation

An alternative synthetic approach to diaryl ethers has been developed. In the key transformation, Robinson annulation of nonracemic aldehydes 16a,b, derived from L-glutamic acid 5-methyl ester and phenoxymethylvinyl ketone, provided α-phenoxyenones 17a,b.

Conjugate addition to chiral γ-heterosubstituted δ-lactones as pivotal synthons from L-glutamic acid. Synthesis of an optically active lignan lactone; (-)-hinokinin

Asymmetric induction in conjugate addition of new chiral γ-heterosubstituted-α, β-unsaturated δ-lactones from L-glutamic acid was accomplished in high diastereoselectivity with the formation of trans-(R,S)-adducts and was disclosed to serve as a versatile procedure for the asymmetric synthesis of antileukemic lignan lactones.